Literature DB >> 25246296

High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink?

Mohamad Mohty1, Florent Malard2, Bipin N Savani3.   

Abstract

Over the last decade, the care of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) has significantly improved, leading to a decrease in deaths related to allo-HCT as well as improved long-term survival. However, for many patients, long-term survivorship is associated with a substantial burden of chronic morbidities. Indeed, malignant and nonmalignant late complications after allo-HCT are numerous and usually multifactorial, with all organs and tissues a potential target. In many cases, these long-term side effects are associated with the use of high-dose total body irradiation, myeloablative conditioning regimens, and the onset of chronic graft-versus-host disease. It appears to be essential to change the natural history of these late effects. This requires the introduction of improved conditioning regimens and the development of lifelong monitoring controls, patient counseling, and preventative treatment measures. This approach will allow us to pursue our efforts to improve patient outcome.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; High-dose total body irradiation; Long-term complication; Myeloablative conditioning regimen; Nonrelapse mortality; Overall survival

Mesh:

Year:  2014        PMID: 25246296     DOI: 10.1016/j.bbmt.2014.09.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

1.  To RIC or not to RIC: that is the question.

Authors:  M Mohty; F Malard
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

2.  Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center.

Authors:  W P Miller; R Shanley; P Dorostkar
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

3.  Promising role of filgrastim and α-tocopherol succinate in amelioration of gastrointestinal acute radiation syndrome (GI-ARS) in mice.

Authors:  Heba A Gheita; Walaa A El-Sabbagh; Rania M Abdelsalam; Amina S Attia; Mona A El-Ghazaly
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-27       Impact factor: 3.000

4.  Evaluation of volumetric modulated arc therapy (VMAT) - based total body irradiation (TBI) in pediatric patients.

Authors:  Kadir Yaray; Edrine Damulira
Journal:  Rep Pract Oncol Radiother       Date:  2021-08-12

Review 5.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

Review 6.  Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Authors:  Courtney D Fitzhugh; Emmanuel J Volanakis; Ombeni Idassi; Josh A Duberman; Michael R DeBaun; Debra L Friedman
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

7.  Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

Authors:  Mohamad Mohty; Florent Malard; Didier Blaise; Noel Milpied; Gérard Socié; Anne Huynh; Oumédaly Reman; Ibrahim Yakoub-Agha; Sabine Furst; Thierry Guillaume; Resa Tabrizi; Stéphane Vigouroux; Pierre Peterlin; Jean El-Cheikh; Philippe Moreau; Myriam Labopin; Patrice Chevallier
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

8.  Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.

Authors:  H Nakasone; T Fukuda; J Kanda; T Mori; S Yano; T Kobayashi; K Miyamura; T Eto; H Kanamori; K Iwato; N Uchida; S Mori; T Nagamura-Inoue; T Ichinohe; Y Atsuta; T Teshima; M Murata
Journal:  Bone Marrow Transplant       Date:  2014-12-22       Impact factor: 5.483

Review 9.  Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation.

Authors:  Todd V Brennan; Victoria R Rendell; Yiping Yang
Journal:  Front Immunol       Date:  2015-03-16       Impact factor: 7.561

Review 10.  NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation.

Authors:  Paola Vacca; Elisa Montaldo; Daniele Croxatto; Francesca Moretta; Alice Bertaina; Chiara Vitale; Franco Locatelli; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Front Immunol       Date:  2016-05-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.